A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer

PURPOSE: Previous studies suggest that a cumulative cisplatin dose of 200 mg/m(2) might be adequate in the intensity-modulated radiation therapy (IMRT) era for locoregionally advanced nasopharyngeal carcinoma (LANPC). However, two cycles of once-every-3-weeks cisplatin at 100 mg/m(2) has never been...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Wei-Xiong, Lv, Xing, Liang, Hu, Liu, Guo-Ying, Sun, Rui, Zeng, Qi, Li, Si-Wei, Mo, Hao-Yuan, Han, Fei, Luo, Dong-Hua, Liu, Qing, Shi, Meng-Yun, Ye, Yan-Fang, Yang, Jing, Ke, Liang-Ru, Qiang, Meng-Yun, Qiu, Wen-Ze, Yu, Ya-Hui, Liu, Kui-Yuan, Huang, Xin-Jun, Li, Wang-Zhong, Lv, Shu-Hui, Cai, Zhuo-Chen, Miao, Jing-Jing, Guo, Ling, Chen, Ming-Yuan, Cao, Ka-Jia, Wang, Lin, Zhao, Chong, Huang, Pei-Yu, Chen, Qiu-Yan, Hua, Yi-Jun, Tang, Lin-Quan, Qian, Chao-Nan, Mai, Hai-Qiang, Guo, Xiang, Xiang, Yan-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974421/
https://www.ncbi.nlm.nih.gov/pubmed/34083231
http://dx.doi.org/10.1158/1078-0432.CCR-20-4532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974421/
https://www.ncbi.nlm.nih.gov/pubmed/34083231
http://dx.doi.org/10.1158/1078-0432.CCR-20-4532

Ejemplares similares